The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
Translational Cancer Research · 2023-03 · 12 (3) · 680-683
DOI: 10.21037/tcr-22-2843 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Cancer Research, 2023-03. Verfasst von Marie-Helene Denault und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumologie, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Programmed death ligand-1 (PD-L1) tumor proportion score (TPS), although imperfect, is the best biomarker identified so far to guide the treatment of metastatic non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICI).Landmark trials in the firstline metastatic setting support its predictive value for response to immunotherapy in this population (1,2).As such, international guidelines recommend single agent anti-PD-1/ PD-L1 treatment in the PD-L1 ≥50% population, while those agents should be combined with either chemotherapy, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or both in PD-L1 1-49% and
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pneumologie, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada.
- Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Zitieren
APA
Denault, M. H., & Ho, C. (2023). The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management. Translational Cancer Research, 12(3), 680-683. https://doi.org/10.21037/tcr-22-2843
Vancouver
Denault MH, Ho C. The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management. Translational Cancer Research. 2023;12(3):680-683. doi:10.21037/tcr-22-2843
BibTeX
@article{Denault2023,
author = {Denault, Marie-Helene and Ho, Cheryl},
title = {The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management},
journal = {Translational Cancer Research},
year = {2023},
volume = {12},
number = {3},
pages = {680--683},
doi = {10.21037/tcr-22-2843}
}
EUVIMED